LON:VEC Vectura Group (VEC) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Vectura Group Stock (LON:VEC) Get Vectura Group alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume203,761 shsAverage Volume3.37 million shsMarket Capitalization£1.01 billionP/E Ratio8.20Dividend Yield23.06%Price TargetN/AConsensus RatingN/A Company Overview Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri, Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta, Anoro Ellipta, and Trelegy Ellipta for the treatment of COPD. It is also developing VR315 (US) for the treatment of asthma and COPD.In addition, the company offers dry powder inhalers, pressurized metered dose inhalers, and nebulized devices. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom. Read More Receive VEC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vectura Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VEC Stock News HeadlinesPhilip Morris Intl.'s Vectura Fertin Pharma To Sell Vectura Group To Molex AsiaSeptember 17, 2024 | markets.businessinsider.comPhilip Morris to Sell UK Inhaler Maker Vectura at a LossSeptember 17, 2024 | bloomberg.comThe chipmaker 148 times smaller than NVIDIA supplying MuskAccording to Yahoo Finance, Elon Musk's latest project could 'upend another industry just as he did with cars and rockets.' Tech investor Jeff Brown - a former senior executive at Qualcomm, Juniper Networks, and NXP Semiconductors - says one tiny chipmaker, 148 times smaller than NVIDIA, is set to supply Musk with 5 billion chips over the next two years. Early investors in Tesla and SpaceX saw life-changing returns. Brown believes this overlooked chipmaker could offer a similar opportunity, with entry points currently around $50.July 4 at 1:00 AM | Brownstone Research (Ad)Philip Morris to sell stake in pharma unit Vectura for $198 millionSeptember 17, 2024 | msn.comPhilip Morris unloads Vectura to Molex Asia for $198M in upfront paymentsSeptember 17, 2024 | msn.comPhilip Morris to Take $220 Million Loss on Sale of Inhaled-Medicine UnitSeptember 17, 2024 | wsj.comAptar Pharma Enters into Exclusive Agreement with Pulmotree to Develop and Promote Kolibri™ Non-Propellant Liquid Inhaler PlatformSeptember 10, 2024 | finance.yahoo.comZengun Group AB: Zengun Group AB (publ) Interim Report January - June 2024August 29, 2024 | finanznachrichten.deSee More Headlines VEC Stock Analysis - Frequently Asked Questions How do I buy shares of Vectura Group? Shares of VEC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Vectura Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vectura Group investors own include Hikma Pharmaceuticals (HIK), SEB (SKP), BTG (BTG), iRobot (IRBT), Sinclair Pharma (SPH), Taylor Wimpey (TW). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Major Sub-IndustryN/A Current SymbolLON:VEC CIKN/A Webwww.vectura.com Phone+44-1249-667700FaxN/AEmployees9,200Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio8.20 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.77 Current Ratio3.59 Quick Ratio3.20 Sales & Book Value Annual Sales£190.60 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow12.48 Book ValueGBX 91.70 per share Price / BookN/AMiscellaneous Outstanding Shares613,892,000Free FloatN/AMarket Cap£1.01 billion OptionableNot Optionable BetaN/A The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (LON:VEC) was last updated on 7/4/2026 by MarketBeat.com Staff. From Our PartnersTwo Legends Issue Rare Buy Alert on Elon Musk SupplierJeff Brown and Marc Chaikin - the two investors who picked Nvidia before it climbed as much as 36,000% - are i...Brownstone Research | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredHe turned $12,415 into millions. Now he wants to help you.Tim Sykes turned $12,415 in bar mitzvah money into over $7 million in trading profits - and more than 50 of hi...Tim Sykes | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredUrgent exposé on the "Mar-a-Lago Trade"Dr. David Eifrig, former Goldman Sachs VP and Senior Partner at Stansberry Research, has released an urgent ex...Stansberry Research | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | Sponsored**MARKET CRASH WARNING**A former advisor to the Pentagon and CIA is warning that an 80% Dow drop could arrive within days - and names ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vectura Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Vectura Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.